In this episode, Paul Bennett delivers a mid-year update on the state of self-storage and small-bay industrial real estate. Paul unpacks current market trends, including shifts in occupancy, rent growth, and the increasing institutional interest in small-bay properties. You will gain practical insights into regional opportunities, supply constraints, and why now may be a rare window for investors looking to capitalize on these asset classes. Tune in to hear expert analysis and firsthand market perspective from one of the industry's most experienced operators.Ready to talk about your investment strategy? Reach out at aaastorageinvestments.comNew episodes every two weeks. Subscribe on Apple Podcasts, Spotify, or wherever you listen to podcasts, and send this to an investor in your network who needs to hear it.Chapters(00:00) Midyear Self Storage Market Overview(04:11) In-Place Rent Growth and Occupancy Trends(07:11) Regional Performance and Market Dynamics(13:30) Limitations of REIT Data for Investment Decisions(16:08) Small-Bay Industrial Market Strength(21:03) Supply Constraints and Investment Window(24:41) Key Growth Markets and Strategic FocusFollow and Connect with Us• LinkedIn: https://www.linkedin.com/company/aaa-storage-investments/• Instagram: https://www.instagram.com/aaastorageinvestments/• X: https://x.com/investments_aaa• Facebook: https://www.facebook.com/people/AAA-Storage-Investments-LLC/61575027573292/Download our free guides to take your investing to the next level:10 Due Diligence Questions to Vet Any Real Estate Sponsor: https://www.aaastorageinvestments.com/info/10-due-diligence-questions-to-vet-any-real-estate-sponsorFirst-Time Real Estate Syndication Investor Checklist: https://www.aaastorageinvestments.com/info/first-time-real-estate-syndication-investor-checklist

On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe burn injury). The TRACK trial lacked any pre-specified futility criteria, with a DSMB-initiated stop based on conditional power calculations. Scott argues that conditional power, especially in this interim context, is a poor, misleading tool—contrasting it against a Bayesian predictive probability calculation that produced a much lower and more realistic estimate of success. In VICTORY, a pre-specified risk ratio threshold for futility was incorporated, with simulation confirming minimal effect on bias and statistical power. Scott underscores the practical and ethical importance of rigorously pre-specified, simulation-based futility rules and operationalizes the case for Bayesian predictive probability as a decision metric in interim monitoring. He reiterates that responsibility for defining futility belongs to trial designers, not left to ad hoc DSMB judgment, and calls for precise statistical planning in adaptive trial protocols.Key HighlightsTRACK: No pre-specified futility rule; DSMB stopped for futility using conditional power post hoc.Technical critique of conditional power as misguided at interim, supporting Bayesian predictive probability instead.VICTORY: Pre-specified futility threshold, with simulation confirming minimal operational bias and power reduction.Emphasizes pre-specified, simulation-based futility planning and predictive probability monitoring as standards for all trials.For more, visit us at https://www.berryconsultants.com/

Join us for this episode of AWM Insights as portfolio manager Mena Hanna sits down with Roger Ferguson, AWM's venture and private equity specialist and a former professional athlete. Together, they break down the recent SpaceX IPO, exploring what it means for investors—whether you’re early to the game, joining the retail wave, or navigating complex private market access. Roger and Mena share inside stories, sharp perspectives on venture capital, and practical strategies for building lasting wealth while avoiding costly mistakes. If you’ve ever wondered how the pros approach headline-making investments and what really matters when chasing generational returns, this episode is a must-listen.Chapters(00:00) Introducing the Team and Guest Insights(01:34) SpaceX IPO Highlights and Market Dynamics(05:00) Timing and Outcomes for Investors(08:00) Access Strategies and Fee Structures(10:14) Long-Term Approach and Diversification(12:40) Venture Fund Concentration and Market Efficiency(15:23) Retail Investor Impact and LessonsConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

In this episode of AWM Insights, hosts Justin Dyer and Mena Hanna break down the buzz surrounding the historic SpaceX IPO. They examine the mechanics behind the IPO's massive valuation, offer candid opinions on market hype and intentional scarcity, and discuss the psychological traps that lure investors into chasing big headlines. With a clear-eyed look at risk, FOMO, and disciplined investing, this conversation brings professional expertise to one of the most talked-about financial events of the year. Whether you're curious about SpaceX or looking to sharpen your investment playbook, you won't want to miss these timely insights.Chapters(00:00) SpaceX IPO as a Historic Market Event(02:00) Share Structure and Intentional Scarcity(03:40) IPO Pricing Dynamics and Market Patterns(06:20) Hype, Human Behavior, and FOMO(08:30) Fundamentals vs. Valuation Concerns(12:04) AWM’s Long-Term Investing Approach(13:30) The Smart Entry Point and Investment DisciplineConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine response-adaptive randomization (RAR) in clinical trials, dissecting its statistical rationale, common criticisms, and implementation challenges. Drawing on extensive experience with trials such as BAN2401 (lecanemab), ICECAP, dulaglutide seamless Phase 2/3, I-SPY2, REMAP-CAP, PROSPECT, and the historical ECMO trial, they discuss the scientific advantages and disadvantages and ethical impact. RAR reallocates patient assignments during interim analyses to direct more patients to better-performing arms, but this can reduce power in two-arm trials, introduce complexity from temporal trends, and create operational complexity. The ECMO trial and "play-the-winner" approaches are discussed as cautionary examples emphasizing the need for thorough simulation before deployment. The hosts highlight RAR’s strengths for dose-finding, multi-arm, and some platform designs, but underscore its limitations in confirmatory two-arm settings. Operational demands, data reliability, simulation across scenarios, and resistance to overgeneralization are recurrent themes. The episode concludes by situating RAR within the broader context of adaptive platform trials and learning healthcare systems.Key HighlightsDefinition and mechanics of RAR, with interim analysis guiding allocation updatesMulti-arm adaptive and platform trial experiences (BAN2401, ICECAP, dulaglutide, I-SPY2, REMAP-CAP, PROSPECT)Critique of RAR in two-arm trials (power loss), temporal trends, unblinding, and overgeneralized literatureECMO/play-the-winner: risks of poorly simulated RARNecessity for rigorous pre-trial simulation and robust data flowsContextualization of RAR’s role in both traditional and learning healthcare environmentsFor more, visit us at https://www.berryconsultants.com/